Last reviewed 2026-06-01 · How we verify

Atibuclimab

Implicit Bioscience · Phase 2 active Biologic

Atibuclimab is a Biologic drug developed by Implicit Bioscience. It is currently in Phase 2 development. Also known as: IC14.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Atibuclimab
Also known as	IC14
Sponsor	Implicit Bioscience
Modality	Biologic
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

IC14 for Treatment of Acute Decompensated Heart Failure (PHASE1, PHASE2)
Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI (PHASE1, PHASE2)
IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy (PHASE1, PHASE2)
Pilot and Feasibility Study of Intra-articular Anti-CD14 for the Treatment of Knee Osteoarthritis (PHASE1)
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Atibuclimab CI brief — competitive landscape report
Atibuclimab updates RSS · CI watch RSS
Implicit Bioscience portfolio CI

Frequently asked questions about Atibuclimab

What is Atibuclimab?

Atibuclimab is a Biologic drug developed by Implicit Bioscience.

Who makes Atibuclimab?

Atibuclimab is developed by Implicit Bioscience (see full Implicit Bioscience pipeline at /company/implicit-bioscience).

Is Atibuclimab also known as anything else?

Atibuclimab is also known as IC14.

What development phase is Atibuclimab in?

Atibuclimab is in Phase 2.

Manufacturer: Implicit Bioscience — full pipeline
Therapeutic area: All drugs in Other
Also known as: IC14

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing